<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82840">
  <stage>Registered</stage>
  <submitdate>22/05/2008</submitdate>
  <approvaldate>26/05/2008</approvaldate>
  <actrnumber>ACTRN12608000265370</actrnumber>
  <trial_identification>
    <studytitle>A pilot study on the cutaneous toxicities in oncology patients on Epidermal Growth Factor Receptor inhibitors: skin physiology, clincial manifestations and quality of life.</studytitle>
    <scientifictitle>Quantifying physiological skin changes and quality of life in oncology patients on epidermal growth factor receptor inhibitors (EGFRIs) compared to normal participants not on EGFRIs. Can physiological skin changes be used to quantify cutaneous toxicities and evaluate subclinical changes before overt disease in order to prevent and minimise these side effects.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cutaneous side effects on oncology patients on EGFRIs</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Normal skin development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A pilot study assessing physiological skin changes using transepidermal water loss (TEWL), skin pH, skin surface hydration, skin sebum levels, skin surface perfusion and microbiological swabs and culture in conjunction with clinical photography and the Dermatology Quality of Life Index (DQLI) in oncology patients on EGFRIs for a period of 3 months.</interventions>
    <comparator>Patients from outpatients/wards that are not on EGFRIs will act as controls for a one-off measurement of TEWL, skin pH, skin surface hydration, skin sebum levels, skin surface perfusion and DQLI</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>transepidermal water loss using Tewameter</outcome>
      <timepoint>at baseline, day 3, day 6, day 9, week 2, week 3, week 4, week 6,week 8, week 10 and week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>skin pH, sebum and hydration using Derma Unit SSC3 (3 combined unit: Sebumeter/Corneometer/Skin-pH-Meter)</outcome>
      <timepoint>at baseline, day 3, day 6, day 9, week 2, week 3, week 4, week 6,week 8, week 10, week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>skin surface perfusion using laser perfusion doppler imager</outcome>
      <timepoint>at baseline, day 6, week 2, week 4 ,week 8 and week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>clinical photography using a standard 5 megapixel digital camera</outcome>
      <timepoint>depend on onset and severity of skin side effects</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>microbiology swab and culture</outcome>
      <timepoint>depend on onset and severity of skin side effects</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dermatology Quality of Life Index (DQLI)</outcome>
      <timepoint>at baseline, week 2, week 4, week 8, week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Oncology patients about to start EGFRIs
male or female
aged 18 years or above
willing to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Younger than 18 years of age
severe underlying disease that may interfere with the testing or test results</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Linda Wang</primarysponsorname>
    <primarysponsoraddress>Liverpool Hospital
Department of Dermatology
(UNSW clinical school)
45-47 Goulburn St, Liverpool 2170</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Linda Wang</fundingname>
      <fundingaddress>Liverpool Hospital
Department of Dermatology
(UNSW clinical school)
45-47 Goulburn St, Liverpool 2170</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr John Sullivan</sponsorname>
      <sponsoraddress>Liverpool Hospital
Department of Dermatology
(UNSW clinical school)
45-47 Goulburn St, Liverpool 2170</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Epidermal growth factor receptor inhibitors (EGFRIs) have been shown efficacy in the treatment of several cancers but despite their potential to be revolutionary therapeutic agents, they are commonly associated with undesirable skin side effects, some of which are chronic or have profound physical and psychosocial impact on patients. This study aims to assess physiological skin changes in patients on EGFRIs using transepidermal water loss (TEWL), skin pH, skin sebum levels, skin surface hydration and surface perfusion measurements in conjunction with microbiology swabs, clinical photography and the Dermatology Quality of Life Index (DQLI) in order to understand the pathophysiology of cutaneous side effects, better characterise these toxicities using a refined classification system and evaluate subclinical changes before overt disease in order to prevent and minimise cutaneous side effects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Limited</ethicname>
      <ethicaddress>First Floor
71 Anzac Highway
Ashford SA 5035</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>28/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Linda Wang</name>
      <address>Liverpool Hospital
Department of Dermatology
(UNSW clinical school)
45-47 Goulburn St, Liverpool 2170
mail to locked bag 7103</address>
      <phone>0410556918</phone>
      <fax>98284639</fax>
      <email>z3159540@student.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Linda Wang</name>
      <address>Liverpool Hospital
Department of Dermatology
(UNSW clinical school)
45-47 Goulburn St, Liverpool 2170
mail to locked bag 7103</address>
      <phone>0410556918</phone>
      <fax>98284639</fax>
      <email>z3159540@student.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>